PetIQ Inc (NASDAQ:PETQ) Given Average Rating of “Buy” by Analysts

Share on StockTwits

PetIQ Inc (NASDAQ:PETQ) has been assigned an average recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $40.71.

A number of research firms recently issued reports on PETQ. BidaskClub downgraded shares of PetIQ from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 9th. Zacks Investment Research downgraded shares of PetIQ from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 5th. ValuEngine downgraded shares of PetIQ from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Guggenheim began coverage on shares of PetIQ in a research report on Thursday, May 23rd. They set a “buy” rating and a $35.00 target price for the company. Finally, Raymond James dropped their target price on shares of PetIQ from $42.00 to $39.00 and set an “outperform” rating for the company in a research report on Monday, March 4th.

Shares of NASDAQ PETQ traded down $0.37 on Friday, reaching $30.12. 25,628 shares of the company traded hands, compared to its average volume of 341,037. PetIQ has a fifty-two week low of $21.29 and a fifty-two week high of $43.93. The firm’s 50 day moving average is $28.79. The company has a quick ratio of 1.51, a current ratio of 2.89 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $859.82 million, a PE ratio of 24.17, a PEG ratio of 1.54 and a beta of 1.88.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.19. The company had revenue of $148.44 million during the quarter, compared to the consensus estimate of $139.03 million. PetIQ had a net margin of 0.51% and a return on equity of 9.47%. As a group, analysts anticipate that PetIQ will post 0.8 earnings per share for the current year.

In related news, Director James Nathan Clarke purchased 31,031 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was purchased at an average price of $28.12 per share, for a total transaction of $872,591.72. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Will Santana sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $27.46, for a total value of $549,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,291 shares of company stock valued at $3,522,291. 23.79% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC purchased a new position in PetIQ in the 1st quarter worth approximately $30,000. Bank of Montreal Can boosted its holdings in PetIQ by 2,007.8% in the 4th quarter. Bank of Montreal Can now owns 1,623 shares of the company’s stock worth $38,000 after acquiring an additional 1,546 shares during the period. Citigroup Inc. boosted its holdings in PetIQ by 43.5% in the 4th quarter. Citigroup Inc. now owns 1,827 shares of the company’s stock worth $43,000 after acquiring an additional 554 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of PetIQ during the 1st quarter valued at approximately $56,000. Finally, Legal & General Group Plc boosted its stake in shares of PetIQ by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,451 shares of the company’s stock valued at $58,000 after buying an additional 732 shares during the last quarter. Hedge funds and other institutional investors own 91.87% of the company’s stock.

About PetIQ

PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.

Featured Article: How can investors find ex-dividend dates?

Analyst Recommendations for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Royal Bank of Canada Trims Russel Metals  Target Price to C$25.00
Royal Bank of Canada Trims Russel Metals Target Price to C$25.00
Turquoise Hill Resources  Cut to “Speculative Buy” at TD Securities
Turquoise Hill Resources Cut to “Speculative Buy” at TD Securities
Western Forest Products  Stock Rating Lowered by Raymond James
Western Forest Products Stock Rating Lowered by Raymond James
Cedar Fair, L.P.  Expected to Earn Q2 2019 Earnings of $0.65 Per Share
Cedar Fair, L.P. Expected to Earn Q2 2019 Earnings of $0.65 Per Share
HELLA GMBH & CO KGAA  PT Set at €43.00 by Goldman Sachs Group
HELLA GMBH & CO KGAA PT Set at €43.00 by Goldman Sachs Group
Duerr  Given a €35.00 Price Target by Deutsche Bank Analysts
Duerr Given a €35.00 Price Target by Deutsche Bank Analysts


 
© 2006-2019 Zolmax.